Clinical trial

A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis

NCT00550446

Study summary

ClinicalTrials.gov

A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

7 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Adalimumab Normalized identity: adalimumab View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention CP-690-550 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention CP-690,550 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-09-01

PhasePHASE2

Conditions

Arthritis, Rheumatoidunresolved

Interventions

AdalimumabDRUG · verified · RxNorm: adalimumab

CP-690-550DRUG

CP-690,550DRUG

PlaceboDRUG

Sponsors & collaborators

Pfizerlead sponsor

Mapped research locations

SofiaBulgaria3 SeoulSouth Korea2 PragueCzechia2 WichitaKansas, United States2 HickoryNorth Carolina, United States2 SantiagoRM, Chile2 DallasTexas, United States1 TampaFlorida, United States1 OrlandoFlorida, United States1 HamburgGermany1 New OrleansLouisiana, United States1 Little RockArkansas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00550446 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.